OFIX Stock — Orthofix Medical Inc

Orthofix Medical Inc (OFIX)

Updated October 16, 2026.

OFIX is a Stock. Total return is -6.2% over the past 34.4 years.

Orthofix Medical Inc. is a medical technology company that manufactures and distributes orthopedic and spine products across two main business segments: Global Spine, which produces bone growth stimulation devices, spine fixation implants, bone graft substitutes, and surgical navigation systems; and Global Limb Reconstruction, which offers products for deformity correction, limb lengthening, and fracture management. The company does not currently have an established distribution schedule. Orthofix sells its products through distributors and direct sales representatives to hospitals, healthcare organizations, and surgical centers worldwide.

OFIX performance

Price and return data through 2026-10-16.

Total return is -6.2% over the past 34.4 years. Over the past year its total return — price change plus distributions reinvested — is -38.5%. Its deepest 1-year drawdown was 46.8%.

OFIX key facts

Asset type

Stock

Asset class

Equity

Inception date

05/18/1992

Distribution frequency

None

Last close

$9.38 (as of 2026-10-16)

Market cap

$382,071,863

Average volume

286064.0

Beta

0.619

Payout ratio

0.0%

Forward P/E

500.0

EPS

$-1.52

How Dividend Vision calculates yield and returns

Distribution rate (the posted rate) uses calculation basis unavailable. Issuer rates can use a different denominator and date, including ex-date NAV. Trailing-12-month yield is the sum of split-adjusted cash distributions with ex-dates in the last 12 months, divided by the published price. It lags a recent raise or cut. Total return uses split-adjusted close with distributions reinvested on the ex-dividend date (a modeling convention, not the cash-settlement date) from the first stored bar on or after inception through the latest bar, compared with the same window on the benchmark. That is the security's total return, not your personal gain/loss.

Yield and safety methodology · Distribution rate methodology · Distribution Safety Score methodology

Sources and review

Primary sources: prices and distributions from Dividend Vision, derived from vendor EOD data.

Reviewed by Bert Sweet, CEO and Co-owner of Dividend Vision. Methodology: Distribution Safety Score.

OFIX risks and drawbacks

The deepest 1-year drawdown on record here is 46.8%.

Who may consider OFIX — and who may not

It is a weaker fit for investors who need monthly cash flow (OFIX does not currently distribute). This is educational context, not a recommendation to buy or sell.

More on OFIX

• All tickers starting with O

Tagged: Healthcare.

Frequently asked questions